- Home
- CBRL vs VERA Comparison
CBRL vs VERA Comparison
Compare CBRL & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRL
- VERA
- Stock Information
- Founded
- CBRL 1969
- VERA 2016
- Country
- CBRL United States
- VERA United States
- Employees
- CBRL N/A
- VERA N/A
- Industry
- CBRL Restaurants
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- CBRL Consumer Discretionary
- VERA Health Care
- Exchange
- CBRL Nasdaq
- VERA Nasdaq
- Market Cap
- CBRL 1.3B
- VERA 1.4B
- IPO Year
- CBRL N/A
- VERA 2021
- Fundamental
- Price
- CBRL $49.59
- VERA $24.54
- Analyst Decision
- CBRL Hold
- VERA Buy
- Analyst Count
- CBRL 8
- VERA 8
- Target Price
- CBRL $55.43
- VERA $64.29
- AVG Volume (30 Days)
- CBRL 2.0M
- VERA 1.8M
- Earning Date
- CBRL 09-17-2025
- VERA 11-06-2025
- Dividend Yield
- CBRL 2.02%
- VERA N/A
- EPS Growth
- CBRL N/A
- VERA N/A
- EPS
- CBRL 2.58
- VERA N/A
- Revenue
- CBRL $3,510,062,000.00
- VERA N/A
- Revenue This Year
- CBRL $2.02
- VERA N/A
- Revenue Next Year
- CBRL $1.69
- VERA N/A
- P/E Ratio
- CBRL $19.23
- VERA N/A
- Revenue Growth
- CBRL 2.84
- VERA N/A
- 52 Week Low
- CBRL $33.86
- VERA $18.53
- 52 Week High
- CBRL $71.93
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- CBRL 37.22
- VERA 58.83
- Support Level
- CBRL $48.66
- VERA $22.72
- Resistance Level
- CBRL $52.96
- VERA $25.29
- Average True Range (ATR)
- CBRL 2.44
- VERA 1.20
- MACD
- CBRL -0.20
- VERA 0.13
- Stochastic Oscillator
- CBRL 6.80
- VERA 81.66
About CBRL Cracker Barrel Old Country Store Inc
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The restaurants of the company are open for breakfast, lunch, and dinner, with menus that offer home-style country food. The company generates maximum revenue from the Restaurants.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.